Rezolute Inc., a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, announced its participation in the BTIG Virtual Biotechnology Conference on July 29-30, 2025. Management will engage in one-on-one investor meetings throughout the event.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.